Senores Pharmaceuticals Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Senores Pharmaceuticals Ltd is ₹ 898.7 as of 30 Apr 15:30 . The P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 2 years The Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 2 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 4 years The revenue of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 178.34 crore as compare to the Sep '25 revenue of ₹ 167.17 crore. This represent the growth of 6.68% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of Senores Pharmaceuticals Ltd for the Dec '25 is ₹ 57.79 crore as compare to the Sep '25 ebitda of ₹ 54.92 crore. This represent the growth of 5.23% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 33.58 crore over 7 quarters. This represents a CAGR of 90.11% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57% The Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Senores Pharmaceuticals Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Senores Pharmaceuticals Ltd is 4,138 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 4,635 Cr

What are the key factors driving the stock performance of Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 4, 2026, the Senores Pharmaceuticals Ltd stock price is INR ₹898.7. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹142.85.

How do dividend payouts of Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Senores Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.